p38 MAPK/Hck tyrosine kinase dual inhibitors (Respivert)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namep38 MAPK/Hck tyrosine kinase dual inhibitors (Respivert)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 γ mitogen-activated protein kinase inhibitorsP38 α mitogen-activated protein kinase inhibitorsTyrosine-protein kinase HCK inhibitors
TargetsTyrosine-protein kinase HCKP38 γ mitogen-activated protein kinaseP38 α mitogen-activated protein kinase
Therapy Area/IndicationsPulmonary Disease, Chronic Obstructive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRespivert Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRespivert Ltd
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic Obstructive

Other Information

ATC CodeN/A
Related LinksN/A